STOCK TITAN

Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Praxis Precision Medicines Inc ownership filing: The Vanguard Group filed an amendment on 03/13/2026 reporting 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Disaggregation reduced reported holdings to zero; reporting now split across Vanguard entities.

The amendment shows The Vanguard Group reporting 0 shares and 0% ownership as of 03/13/2026, citing an internal realignment and reliance on SEC Release No. 34-39538. This is an administrative reallocation of reporting responsibility among Vanguard subsidiaries.

Cash‑flow treatment is not stated; subsequent filings from Vanguard affiliates may show the beneficial positions now reported under different legal entities.






74006W207

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What did The Vanguard Group report for PRAX in this 13G/A?

The Vanguard Group reported 0 shares beneficially owned and 0% of Praxis common stock as of 03/13/2026, attributing the change to an internal realignment and disaggregated reporting by Vanguard subsidiaries.

Why does Vanguard say it now reports zero for PRAX?

Vanguard cites an internal realignment completed on 01/12/2026 and reliance on SEC Release No. 34-39538, which permits subsidiaries to report beneficial ownership separately; the parent no longer deems itself to beneficially own those securities.

Does this filing mean Vanguard sold PRAX shares?

No sale is disclosed in this amendment; the filing attributes the reporting change to organizational realignment and disaggregation under SEC guidance rather than a disclosed transaction or cash proceeds.

Will other Vanguard entities file separate PRAX holdings?

The amendment states Vanguard subsidiaries or business divisions will report separately; investors should expect separate ownership reports from those subsidiaries if they hold Praxis shares, timing not specified in this excerpt.
Praxis Precision Medicines, Inc.

NASDAQ:PRAX

View PRAX Stock Overview

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

8.43B
25.64M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON